P27kif protein levels and E2F activity are targets of Cot kinase during G1 phase progression in T cells

被引:15
作者
Velasco-Sampayo, A [1 ]
Alemany, S [1 ]
机构
[1] Univ Autonoma Madrid, Fac Med, CSIC, Inst Invest Biomed, E-28029 Madrid, Spain
关键词
D O I
10.4049/jimmunol.166.10.6084
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cot/Tpl-2 kinase, homologous to members of mitogen-activated protein kinase kinase kinase, was initially discovered by its capacity to promote cell transformation. Cot/Tpl-2 mRNA levels are increased during G(0) to G(1) phase progression in T lymphocytes, suggesting a role for this kinase later on in the cell cycle. The IL-2-dependent CTLL-2 cells were used to investigate the role of Cot kinase in G(1) to S phase transition. Transient expression of Cot kinase in CTLL-2 cells increases DNA synthesis triggered by IL-2 and the transient expression of a dominant negative form of Cot kinase in CTLL-2 markedly reduces the DNA synthesis triggered by this cytokine. Cell cycle analysis of synchronized CTLL-2 stabling overexpressing Cot kinase indicates that this kinase contributes to the passage to S and GZ-NI phases of the cell cycle. Cot kinase reduces the levels of the cyclin kinase inhibitor p27(kip), whereas bcl-x(L) expression is unaffected. Cot kinase also increases E2F transcriptional activity in a phosphatidylinositol 3 kinase-independent way and acts in synergy with this kinase. These data give evidence, for the first time, of the regulation of different G(1) progression events by Cot kinase.
引用
收藏
页码:6084 / 6090
页数:7
相关论文
共 37 条
[1]   Transduction of interleukin-2 antiapoptotic and proliferative signals via Akt protein kinase [J].
Ahmed, NN ;
Grimes, HL ;
Bellacosa, A ;
Chan, TO ;
Tsichlis, PN .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (08) :3627-3632
[2]   Interleukin-2 receptor common gamma-chain signaling cytokines regulate activated T cell apoptosis in response to growth factor withdrawal: Selective induction of anti-apoptotic (bcl-2, bcl-x(L)) but not pro-apoptotic (bax, bcl-x(S)) gene expression [J].
Akbar, AN ;
Borthwick, NJ ;
Wickremasinghe, RG ;
Panayiotidis, P ;
Pilling, D ;
Bofill, M ;
Krajewski, S ;
Reed, JC ;
Salmon, M .
EUROPEAN JOURNAL OF IMMUNOLOGY, 1996, 26 (02) :294-299
[3]  
AOKI M, 1991, ONCOGENE, V6, P1515
[4]   Cot kinase activates tumor necrosis factor-α gene expression in a cyclosporin A-resistant manner [J].
Ballester, A ;
Velasco, A ;
Tobeña, R ;
Alemany, S .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (23) :14099-14106
[5]  
Ballester A, 1997, J IMMUNOL, V159, P1613
[6]   TPL-2 kinase regulates the proteolysis of the NF-κB-inhibitory protein NF-κB1 p105 [J].
Belich, MP ;
Salmerón, A ;
Johnston, LH ;
Ley, SC .
NATURE, 1999, 397 (6717) :363-368
[7]   Phosphatidylinositol 3-kinase couples the interleukin-2 receptor to the cell cycle regulator E2F [J].
Brennan, P ;
Babbage, JW ;
Burgering, BMT ;
Groner, B ;
Reif, K ;
Cantrell, DA .
IMMUNITY, 1997, 7 (05) :679-689
[8]   Regulation of cyclooxygenase activity by metamizol [J].
Campos, C ;
de Gregorio, R ;
García-Nieto, R ;
Gago, F ;
Ortiz, P ;
Alemany, S .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 378 (03) :339-347
[9]   Tpl-2 is an oncogenic kinase that is activated by carboxy-terminal truncation [J].
Ceci, JD ;
Patriotis, CP ;
Tsatsanis, C ;
Makris, AM ;
Kovatch, R ;
Swing, DA ;
Jenkins, NA ;
Tsichlis, PN ;
Copeland, NG .
GENES & DEVELOPMENT, 1997, 11 (06) :688-700
[10]  
CHAN AML, 1993, ONCOGENE, V8, P1329